Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Employees - 88000,
CEO - Dr. Albert Bourla D.V.M., Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 152.80B
Altman ZScore(max is 10): 1.85, Piotroski Score(max is 10): 6, Working Capital: $12000000, Total Assets: $219476000000, Retained Earnings: $121059000000, EBIT: 6943000000, Total Liabilities: $126918000000, Revenue: $60113000000
AryaFin Target Price - $63.65 - Current Price $26.36 - Analyst Target Price $31.50
| Ticker | PFE |
| Index | S&P 500 |
| Curent Price | 26.36 |
| Change | 2.29% |
| Market Cap | 152.80B |
| Average Volume | 42.12M |
| Income | 4.27B |
| Sales | 60.11B |
| Book Value/Share | 16.29 |
| Cash/Share | 1.72 |
| Dividend Est | 1.67 (6.32%) |
| Dividend TTM | 1.68 (6.37%) |
| Dividend Ex-Date | Jan 24, 2025 |
| Employees | 88000 |
| Moving Avg 20days | 2.33% |
| Moving Avg 50days | -1.96% |
| Moving Avg 200days | -5.76% |
| Shares Outstanding | 5.67B |
| Earnings Date | Oct 29 BMO |
| Inst. Ownership | 67.55% |
| Price/Earnings | 35.43 |
| Forwad P/E | 9.11 |
| PE Growth | 4.69 |
| Price/Sales | 2.54 |
| Price/Book | 1.62 |
| Price/Cash | 15.35 |
| Price/FCF | 18.57 |
| Quick Ratio | 0.73 |
| Current Ratio | 1.00 |
| Debt/Equity | 0.73 |
| Return on Assets | 1.97% |
| Return on Equity | 4.52% |
| Return on Investment | 2.84% |
| Gross Margin | 58.50% |
| Ops Margin | 16.32% |
| Profit Margin | 7.11% |
| RSI | 53.04 |
| BETA(β) | 0.62 |
| From 52week Low | 7.68% |
| From 52week High | -16.42% |
| EPS | 0.74 |
| EPS next Year | 2.90 |
| EPS next Qtr | 0.47 |
| EPS this Year | 58.79% |
| EPS next 5 Year | 7.55% |
| EPS past 5 Year | -27.43% |
| Sales past 5 Year | 10.96% |
| EPS Y/Y | -59.54% |
| Sales Y/Y | -12.29% |
| EPS Q/Q | 284.91% |
| Sales Q/Q | 33.78% |
| Sales Surprise | 18.63% |
| EPS Surprise | 72.53% |
| ATR(14) | 0.61 |
| Perf Week | 3.05% |
| Perf Month | 5.69% |
| Perf Quarter | -10.06% |
| Perf Year | -4.60% |
| Perf YTD | -8.44% |
| Target Price | 31.50 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer